reversed-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-24. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
=== Fatty Acid Synthesis === Fatty acid synthesis begins in the cytosol. During the first reaction, irreversible carboxylation of acetyl-CoA to malonyl-CoA is catalyzed by the biotin-dependent enzyme acetyl-CoA carboxylase (ACC). Notably, the conversion of acetyl-CoA to malonyl-CoA is the rate-limiting step of fatty acid synthesis. Acetyl-CoA carboxylase (ACC) thus represents the rate-limiting enzyme in fatty acid synthesis; ACC activity is stimulated by increasing concentrations of cytosolic citrate, and inhibited by increasing concentrations of the fatty acid palmitate. After malonyl-CoA becomes available by virtue of ACC, fatty acid synthase (FAS) is then able to complete a series of reactions to form the 16-carbon molecule palmitate. FAS is a complex, multifunctional protein containing seven different catalytic sites: acetyl transacylase, malonyl transacylase, β-ketoacyl synthase, β-ketoacyl carrier protein (ACP) reductase, 3-hydroxyacyl-ACP dehydratase, enoyl-ACP reductase, and thioesterase. These different enzymes are covalently linked within the FAS complex, allowing for intermediates to be handled efficiently from one active site to another without leaving the assembly. After the completion of the first reaction by ACC, fatty acid synthesis thus continues on the FAS complex. During the second reaction of fatty acid synthesis, acetyl transacylase and malonyl transacylase catalyze the formation of acetyl-ACP and malonyl-ACP, respectively.
=== Civil operations === An inaugural service from Moscow to Tashkent was flown on December 26, 1980, but services-proper commenced after February 1, 1981. Aeroflot first operated the Il-86 on peak domestic routes. Foreign services began in June 1981 to Eastern Europe. Services to larger West European cities began with the winter timetable starting in October that year. Charter flights to European points followed, with services on high-density medium/long-range routes within the Soviet Union coming last. Although the Il-86 was a medium-range airliner, from 1982 Aeroflot put it into scheduled service from Moscow to Havana via Shannon and Gander, "perhaps with limited payload or with additional tankerage." Other scheduled long-range services flown by the type were to Buenos Aires, Montevideo and Lima, Rio de Janeiro and São Paulo, all via Sal, Cape Verde. After the collapse of the Soviet Union in 1991, national airlines emerged in the 15 successor republics. Il-86s serving with Aeroflot administrations ("Directorates") in these nations accrued to their airlines and many were traded. From April 2002, the European Union, the US and much of the rest of the world banned noisier aircraft, including the Il-86. On October 23, 2006, Aeroflot Deputy Director General Igor Desyatnichenko said that the Il-86 was to be withdrawn from service starting November 15 that year as it operated for just two or three months in the summer."
=== Arabinogalactan sidechains === The structure of the AG glycans consists of a backbone of β-1,3 linked galactose (Gal), with sidechains of β-1,6 linked Gal and have terminal residues of arabinose (Ara), rhamnose (Rha), Gal, fucose (Fuc), and glucuronic acid (GlcA). These AG glycan moieties are assembled by glycosyltransferases (GTs). O-glycosylation of AGPs is initiated by the action of Hyp-O-galactosyltransferases (Hyp-O-GalTs) that add the first Gal onto the protein. The complex glycan structures are then elaborated by a suite of glycosyltransferases, the majority of which are bio-chemically uncharacterized. The GT31 family is one of the families involved in AGP glycan backbone biosynthesis. Numerous members of the GT31 family have been identified with Hyp-O-GALT activity and the core β-(1,3)-galactan backbone is also likely to be synthesized by the GT31 family. Members of the GT14 family are implicated in adding β-(1,6)- and β-(1,3)-galactans to AGPs. In Arabidopsis, terminal sugars such as fucose are proposed to be added by AtFUT4 (a fucosyl transferase) and AtFUT6 in the GT37 family and the terminal GlcA incorporation can be catalysed by the GT14 family. A number of GTs remain to be identified, for example those responsible for terminal Rha.
Sources: en.wikipedia.org
== History == In 1959, physicist Richard Feynman gave a talk titled "There's Plenty of Room at the Bottom" to the American Physical Society. He imagined a world in which "we could arrange atoms one by one, just as we want them." This idea set the stage for the bottom-up synthesis approach in which constituent components interact to form higher-ordered structures in a controllable manner. The study of self-assembly of nanoparticles began with recognition that some properties of atoms and molecules enable them to arrange themselves into patterns. A variety of applications where the self-assembly of nanoparticles might be useful. For example, building sensors or computer chips. Definition Self-assembly is defined as a process in which individual units of material associate with themselves spontaneously into a defined and organized structure or larger units with minimal external direction. Self-assembly is recognized as a highly useful technique to achieve outstanding qualities in both organic and inorganic nanostructures. According to George M.
== Products and services == The major products of the company are Surfaxin (based on its capillary aerosol-generating technology) and Aerosurf. Surfaxin is a synthetic, peptide-containing (KL4) surfactant, similar to pulmonary surfactant, which is naturally in the lung for normal respiratory function. The drug is delivered by its capillary aerosol-generating technology to the lung. Aerosurf is a drug-device combination to prevent respiratory distress syndrome (RDS) in premature infants. In addition, the company also provides Afectair devices (disposable aerosol-conducting airway connectors).
=== Glutaminolysis and transamination === Aside from the citric acid cycle, α-ketoglutarate is made by glutaminolysis in which the enzyme glutaminase removes the amino group from glutamine to form glutamate which is converted to α-ketoglutarate by any one of three enzymes, glutamate dehydrogenase, alanine transaminase, or aspartate transaminase (see The glutaminolytic pathways). It is also made through the action of pyridoxal phosphate-dependent enzymes (alanine transaminase) in which glutamate is converted to α-Ketoglutarate by "donating" its −NH2 to other compounds (see transamination). These reactions are reversible. In the reverse direction of these reactions, α-ketoglutarate contributes to the production of amino acids such as glutamine, proline, arginine, and lysine as well as the lowering of cellular carbon and nitrogen (i.e., N) levels; this prevents excessive levels of these two potentially toxic elements from accumulating in cells and tissues. The neurotoxin, ammonia (i.e., NH3), is also prevented from accumulating in tissues. In this metabolic pathway the −NH2 group on an amino acid is transferred to α-ketoglutarate; this forms the α-keto acid of the original amino acid and the amine-containing product of α-ketoglutarate, glutamate. The cellular glutamate passes into the circulation and is taken up by the liver where it delivers its acquired −NH2 group to the urea cycle. In effect, the latter pathway removes excess ammonia from the body in the form of urinary urea.
Through the centuries, a variety of techniques for processing tea, and a number of different forms of tea, were developed. During the Han and Six Dynasties, tea was steamed and pounded, shaped into cake form, slowly dried over low fire, and suspended to air dry. Chunks of tea were then boiled to drink, flavoured with orange peels, jujube, mint, ginger or scallion. Tea was similarly prepared in cake form during the Tang dynasty, but Lu Yu disparaged the use of various condiments to flavour the tea apart from salt. By the Song dynasty, loose-leaf tea was developed and became common. During the Yuan and Ming dynasties, unoxidized tea leaves were first stirred in a hot dry pan, then rolled and air-dried, a process that stops the oxidation process that would have turned the leaves dark, thereby allowing tea to remain green. In the 15th century, oolong tea, in which the leaves are allowed to partially oxidize before being heated in the pan, was developed. Western tastes, however, favoured the fully oxidized black tea, and the leaves were allowed to oxidize further. Yellow tea was an accidental discovery in the production of green tea during the Ming dynasty, when apparently careless practices allowed the leaves to turn yellow, which yielded a different flavour.
Sources: en.wikipedia.org
=== Genes are commonly interrupted by introns that must be removed by RNA splicing === Analysis of mature eukaryotic messenger RNA molecules showed that they are often much smaller than the DNA sequences that encode them. The genes were shown to be discontinuous, composed of sequences that are not present in the final mature RNA (introns), located between sequences that are retained in the mature RNA (exons). Introns were shown to be removed after transcription through a process termed RNA splicing. Splicing of RNA transcripts requires a highly precise and coordinated sequence of molecular events, consisting of (a) definition of boundaries between exons and introns, (b) RNA strand cleavage at exactly those sites, and (c) covalent linking (ligation) of the RNA exons in the correct order. The discovery of discontinuous genes and RNA splicing was entirely unexpected by the community of RNA biologists, and stands as one of the most shocking findings in molecular biology research.
After the final primary election, Clinton became the presumptive Democratic nominee. On July 12, Sanders formally endorsed Clinton. He said he would continue to work with the Democratic National Convention organizers to implement progressive positions. Sanders refused to formally concede before the convention. He spoke at the 2016 Democratic National Convention on July 25, during which he gave Clinton his full support. Some of his supporters attempted to protest Clinton's nomination and booed when Sanders called for party unity. He responded, "Our job is to do two things: to defeat Donald Trump and to elect Hillary Clinton ... It is easy to boo, but it is harder to look your kids in the face if we are living under a Trump presidency." On November 8, in the general election, Sanders received almost 6% of the vote in Vermont, even though he was no longer a candidate. This was the highest share of a statewide presidential vote for a write-in draft campaign in American history. He also received more votes in Vermont than Gary Johnson, the Libertarian candidate, and Jill Stein, the Green candidate, combined. It was possible to vote for Sanders as a write-in candidate in 12 states, and exact totals of write-in votes for him were published in three of them: California, New Hampshire, and Vermont. In those three states, he received 111,850 write-in votes, about 15% of the write-in votes nationwide, and less than 1% of total nationwide vote.
==== Nanoreactors ==== Enzyme-catalyzed reactions can be performed at higher temperatures using enzyme-immobilized nanoparticles, in which the presence of multiple proteins at the nanoparticle surface facilitates the retention of water molecules limiting the denaturation of the attached proteins. After modification with poly(amide), protein activity could remain unchanged over 500 min at 50 °C, while the half-life time of the native lipase at 50 °C is only 30 min in aqueous solution. Immobilized enzymes on nanoparticles can significantly improve the efficiency of enzyme reactions by increasing tolerance to a wider range of experimental conditions without significantly reducing biological activity. Besides, polymer-protein particles are reported to control the activity of proteins and compartmentalize different enzymes to perform multi-step reactions.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.